There are numerous treatments for multiple sclerosis. If, however, you have relapsing or primary progressive types of MS, one drug that will help is called Ocrevus (ocrelizumab).
Ocrevus Ocrelizumab Multiple Sclerosis Treatment
There are a few things to note if you want to experiment with the Ocrevus Ocrelizumab multiple sclerosis treatment.
How Does it Work?
As of right now, it is unclear as to how Ocrevus (ocrelizumab) helps multiple sclerosis. It is thought to help because Ocrevus binds to CD-20, which is a cell surface antigen that can cause brain damage in MS.
The only active Ocrevus ingredient is ocrelizumab.
It is important to note that taking Ocrevus for multiple sclerosis treatment can cause a few side effects in an individual. It is possible for reactions to occur for roughly 24 hours after a person’s first infusion. The most common side effects are as follows: throat irritation, fever, and upper respiratory tract infections. If you experience fever and flu-like symptoms, know that you can take fever and pain-reducing medications. This will help to reduce the symptoms.
Furthermore, other individuals have experienced side effects like diarrhea, increased risk of developing cancer, and infusion reactions.
Note that Ocrevus comes as a sterile, colourless, and sometimes pale brown, solution. It comes in a single-dose vial. You should know that Ocrevus has to be prepared by someone working in the healthcare sector. This is because they need to create a strict drug concentration.
Additionally, Ocrevus can interact with other medications, so inform your doctor if you are taking any other drugs before taking Ocrevus for multiple sclerosis treatment.
If you are going down the Ocrevus ocrelizumab multiple sclerosis treatment plan route, note the initial dose is 300 mg. It is injected into the skin. Two weeks later, you will have to get another intravenous infusion. You are required to be watched for roughly one hour after each infusion has been administered.
Featured Image: Depositphotos/ ©designer491
Posted on May 5, 2023